Tracking the pathology of Alzheimer's disease

VMA English

Overview

Prof. Lehmann discusses the ATN framework and associated biomarkers

This Class for

  • Physician
  • Resident / Fellow

What I will learn?

1. To Understand the shift in Alzheimer’s diagnosis from a primarily clinical approach to one that incorporates pathological and biomarker-based methods.
2. Identify the different pathological biomarkers for Alzheimer' Disease and how it develops in the patient.





Disclaimer

This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)

For adverse events and safety reporting: email: [email protected]
24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
For Lilly product information: email: [email protected]
For further information, please contact:
Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: [email protected]

PP-AD-SA-0064
  • clock Last Update 10/2024
  • adjust Hosted